HAMILTON, N.J., March 1, 2017 /PRNewswire/ -- Genesis Biotechnology Group (GBG), a consortium of an integrated group of biotechnology and research companies, announced that it has expanded its drug development services by the acquisition of PharmOptima.

PharmOptima, a preclinical Contract Research Organization (CRO) company, joins Invivotek and Venenum Biodesign in the existing drug development segment of GBG. This acquisition expands GBG's catalogue of available services, while providing the same high quality service each company's clients have grown to expect. Effective with this acquisition, GBG will provide new and existing customers with the added value of a single point-of-contact for the efficient development and coordination of their unique preclinical drug development program.

According to Dr. Eli Mordechai, GBG's CEO, "This partnership brings together highly complementary services of three companies creating a dynamic and efficient enterprise that will enable clients to have access to a comprehensive portfolio of bio-analytical and in vivo services in multiple therapeutic areas." This spirit of collaboration was supported by PharmOptima's CEO, Steven Weber, who stated, "PharmOptima is excited to become a part of the GBG consortium that will have the synergistic effect of expanding both the breadth and depth of expertise in advancing the drug development activities of our clients and partners."

About GBG

GBG is a consortium of vertically integrated corporate research entities, which facilitates the overall market implementation and delivery of biomedical science products and services related to diagnostics and drug discovery. Through the consolidation of research activities, and the collaboration of diverse groups of scientists with expertise in molecular biology, genetics, high throughput screening (HTS), pharmacology, molecular modeling, and medicinal chemistry, GBG will be better positioned to create and sustain complex research platforms in drug discovery and the design of surrogate biomarkers for chronic diseases.

About PharmOptima

Since 2003, PharmOptima has been advancing drug discovery and development in various therapeutic areas and has filled a niche in ocular drug development. PharmOptima's in vivo services include studies in the fields of drug absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK), and pharmacology.It provides liquid chromatography and mass spectrometry (LC-MS/MS) bioanalysis in support of discovery and development programs, including method development and validation in accordance with regulatory guidelines.Its biochemistry expertise allows them to assess the role of biomarkers in numerous disease models. PharmOptima's biochemical capabilities include in vitro and cell based assay development for compound profiling as well as protein cloning and expression. Its expertise extends to the custom development of enzyme-linked immunosorbent assays (ELISA) and electrochemiluminescence multiplex formats.

About Invivotek

Invivotek offers both custom and standard preclinical services for drug discovery and development programs for their clients. Services offered by Invivotek include studies in animal models and bioassays to test compounds related to immunology and inflammation, oncology, metabolic and cardiovascular diseases.Invivotek's in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as by functional assays with primary cell cultures. These assays provide tools to study the mechanisms of action of various test therapeutics or potential target genes and to explore biomarkers for drug efficacy. Invivotek's experience across multiple therapeutic areas and its efficient project management, positions the company as a leading provider of preclinical in vivo services.

About Venenum Biodesign

Venenum Biodesign (Venenum) focuses on the identification of potentially therapeutic compounds starting with ultra-high throughput screening (UHTS) against their proprietary 5.5 million ECLiPS compound collection. Compounds identified by UHTS are advanced into preclinical drug candidates using in-house medicinal chemistry, crystallography and molecular modeling. Venenum's drug discovery biology capabilities are supported by expertise in in vitro andcell-based assay development, protein expression and purification, and assay reagent generation. Venenum has extensive experience working in a wide variety of therapeutic areas with conventional target classes, such as G protein-coupled receptors (GPCRs), enzymes, nuclear hormone receptors (NHRs), as well as with protein-protein or protein-DNA interactions.

Read More

More here:
Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima - Yahoo Finance

How to Trade these Stock After an unavoidable Selloff: Puma Biotechnology, Inc. (PBYI), BofI Holding, Inc. (BOFI) StockNewsJournal Puma Biotechnology, Inc. (NASDAQ:PBYI) market capitalization at present is $1.42B at the rate of $37.80 a share. The firm's price-to-sales ratio was noted 0.00 in contrast with an overall industry average of 100.20. Most of the active traders and ... and more »

Visit link:
How to Trade these Stock After an unavoidable Selloff: Puma Biotechnology, Inc. (PBYI), BofI Holding, Inc. (BOFI) - StockNewsJournal

New Delhi: The Department of Biotechnology has invited applications from eligible candidates for admission to Molecular Biology and Biotechnology for Fisheries Professionals. This program is completely sponsored by Department of Biotechnology, Govt. of India.

The three-month training program comprises 45 days of theory classes with hands-on practical sessions and 45 days of research work. All basic molecular biology and genetic engineering and molecular genetics techniques are included in the course along with their applications in various aspects of aquaculture and fisheries.

Participants are also expected to prepare research proposals and reports in DBT prescribed formats to familiarize them with the procedure of seeking extramural funding from DBT or other funding agencies.

Programme dates: CIFA & CMFRI : 15 Feb to 13 May 2017 CIFE : 7 March to 6 Jun 2017 CIFA, CMFRI and CIFE : 01.11.2017 to 30.01.2018

Eligibility Assistant Professors/ Scientists and above/ Post-doctoral fellows employed in SAUs, CAUs, Fisheries Colleges, research institutes, traditional universities and engaged in research and teaching in the area of aquaculture, sheries, marine biology, aquatic biology and allied disciplines.

Selection of participants: The total number of participants will be 10 at each collaborating institute. Selection letters will be communicated 20 days prior to the start date of the programme subject to receiving duly forwarded applications.

For more details, visit http://www.dbtindia.nic.in/

View original post here:
Training in Molecular Biology, Biotechnology - Mathrubhumi English

Patch.com

Minuteman HS Receives Biotechnology Lab Grant Patch.com From Minuteman HS:Minuteman High School has landed another major grant from the Massachusetts Life Sciences Center to help upgrade its Biotechnology program. The $108,172 competitive grant will enable the school to outfit its Biotechnology lab with ...

Read the original here:
Minuteman HS Receives Biotechnology Lab Grant - Patch.com

March 1 Puma Biotechnology Inc:

* Puma Biotechnology provides update on review of marketing authorisation application for PB272

* Puma Biotechnology Inc - company plans to modify summary of product characteristics in its marketing authorisation application

* Puma Biotechnology-plans to modify summary of product characteristics based on meeting with rapporteur, co-rapporteur, review team members, EMA

* Puma Biotechnology - proposed summary of product characteristics will continue to include both hormone receptor positive, hormone receptor negative patients

* Puma-Will be revising proposed smpc for neratinib to restrict intended population to patients within a year after completion of Adjuvant Trastuzumab Therapy

* Puma-Committee for medicinal products for human use continuing to review co's maa and has not yet made a final decision to recommend approval of drug Source text for Eikon: Further company coverage:

BRUSSELS, March 2 Anheuser-Busch InBev, the world's largest brewer, raised its forecast for savings from its near $100 billion takeover of SABMiller after weaker than expected earnings as beer sales suffered in Brazil.

TOKYO, March 2 Japan's Nikkei share average hit a 14-month peak on Thursday as the yen weakened against the dollar on heightened expectations for the Federal Reserve to raise interest rates this month and after Wall Street soared to record highs.

* Acquired privately held Ontology Systems for a total consideration of US$7.6 million, net of cash

Read more from the original source:
BRIEF-Puma Biotechnology provides update on review of marketing authorisation application for PB272 - Reuters

Cellect Biotechnology Ltd. (NASDAQ: APOP)

Cellect Biotechnology is having an incredibly strong day in the market today. As soon as the session opened, the stock was already trading on overwhelmingly impressive gains. From there, we've seen a continuation of strong movement. Below, we'll talk about what we're seeing from the stock, why, and what we'll be watching for with regard to APOP ahead.

As mentioned above, Cellect Biotechnology is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. Throughout the morning, we've seen a continuation of gains. At the moment (10:52), APOP is trading at $6.91 per share after a gain of $1.08 per share (18.52%) thus far today.

As is almost always the case, our partners at Trade Ideas were the first to send the alert that APOP was making a run for the top. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn't take long to uncover the story. The gains are ultimately the result of a positive data release.

Early this morning, Cellect Biotechnology released positive results from its clinical trial of ApoGraft(TM). The point of the study was to validate the company's proprietary method for stem cell selection. To do so, the company went through the process of production and characterization through ApoGraft. In the announcement, investors learned that the company met its primary endpoint in this study.

Moving forward, the CNA Finance team will continue to keep a close eye on APOP. In particular, we're following ongoing work with regard to ApoGraft as well as the rest of the company's pipeline. We'll keep a close eye on the news and continue to bring it to you as it breaks!

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

More here:
Cellect Biotechnology (APOP) Stock: Gaining Big On Positive Clinical Data - CNA Finance (press release)

MPs on Tuesday clashed with biotechnology researchers over the lifting of the GMO ban.

The law makers dismissed a call to have the ban lifted and called for development of home grown biotechnology solutions rather than imposing "foreign ideologies".

Our researchers should focus on home grown technologies that address some of the challenges farmers are facing such as aflatoxin, drought tolerant crop varieties and the stem borer pest, said Agriculture Parliamentary committee chair Noor Mohammed.

He assured local scientists that as long as they focus on need based research, the committee will lobby the government to allocate more resources.

Mohammed made the remarks during a consultative meeting between the committee and biotechnology stakeholders.

He noted that there has not been any scientific evidence on the safety of GMOs, or any guarantee that it can offer a solution to food insecurity in the country.

Read: University students want government to issue licence of GMO maize

Also read: State launches GMO labelling mark amid jitters of effect on existent ban

There is no research in the world specifically stating on the safety of the technology. Let any scientist give evidence in Kenya own up and that GMO is safe for human consumption, he said.

Mohammed stated that MPs remarks should not be construed to mean that the political class in the country is against the introduction of GMO, but warned the researchers and other experts against issuing conflicting statements.

He said all the Parliamentary committees - health, agriculture, environment, education - and all the biotechnology researchers need to work together with a view to providing a common approach regarding the issue.

Dr Margaret Karembu emphasised on the need by the government to allow application of GMO as one of the tools to taming food insecurity and enhancing agricultural productivity.

Any country that does not give opportunity to researcher will forever rely on other peoples products. GMOs have been proven safe by the World Health Organization and other global biotechnology players, said Karembu.

Willy Tonui, the National Biosafety Authority CEO, assured Kenyans that there is no GMO product in the market and that the government is vigilant in monitoring all the foreign materials that are being imported in the county.

View original post here:
MPs clash with biotechnology researchers over GMO ban | The Star ... - The Star, Kenya

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) traded on unusually high volume on Feb. 21, as the stock lost 4.72% to close at $38.35. On the day, Puma Biotechnology Inc saw 1.1 million shares trade hands on 8,009 trades. Considering that the stock averages only a daily volume of 715,433 shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $73.27 and $19.74 over the last 52-weeks, its 50-day SMA is now $34.44, and its 200-day SMA $41.65. Puma Biotechnology Inc has a P/B ratio of 15.46.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Headquartered in Los Angeles, CA, Puma Biotechnology Inc has 156 employees and is currently under the leadership of CEO Alan H. Auerbach.

For a complete fundamental analysis analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

See the original post:
Puma Biotechnology Inc (PBYI) Moves Lower on Volume Spike for February 21 - Equities.com

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a good day on the market for Friday February 17 as shares jumped 7.76% to close at $40.25. About 1.37 million shares traded hands on 9,969 trades for the day, compared with an average daily volume of 928,303 shares out of a total float of 36.82 million. After opening the trading day at $37.25, shares of Puma Biotechnology Inc stayed within a range of $40.50 to $36.70.

With today's gains, Puma Biotechnology Inc now has a market cap of $1.48 billion. Shares of Puma Biotechnology Inc have been trading within a range of $73.27 and $19.74 over the last year, and it had a 50-day SMA of $34.47 and a 200-day SMA of $41.58.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 156 employees. Its CEO is Alan H. Auerbach.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Read this article:
Puma Biotechnology Inc (PBYI) Soars 7.76% on February 17 ... - Equities.com

The Indian Express

National Agri-Food Biotechnology Institute celebrates seventh foundation day The Indian Express The National Agri-Food Biotechnology Institute, Mohali, on Saturday observed its 7th foundation day at the NABI premises at Phase 8 in Mohali. The NABI is an autonomous institute aided by the department of Biotechnology, Government of India, and ...

View post:
National Agri-Food Biotechnology Institute celebrates seventh foundation day - The Indian Express

Xn`Dr(6bE3s8zfPF$=$;a{w|3%o !m~>ZxN&zUV2mMUt#rk75nLMmukVqnpC3B|l;#kjB|lFCQ|O3+ob9;]Kkt7+} Zx9GhBNz)Q;% m=Y# rwHj[p1_QVDCDbhA]kS^W_E]-0_.L,ka=4wlNa#.r=`GZ7&?zZO}O #:ZOzQ{4: i>|Ua/pN Zhh_$,maG>k!@V@F44LzO^5 LDAVqQq.!R_@Ol

+mYZQe,nFppP=1 u=uB~:= F'Iwv}%qJ a$xIOHr4gguI |xP_U7'G+q#pp"rL~:0]X~8gNDs/kO8T:U(4Xvo1%RDIc+xGY.gY>$">s0TK<8K@.H_Uzx HTwV-VNgNt)9~S< V3+= g3qiB;}q'mjk!yq*c~lLz?S-S@6vxbyT(@i joTAhk$f:D1Kfg+PhqhFc'#`YeU`bN.ywyi%u]8'QJ7t{M XafnC&Pu6gQX%'88V rh4uc?[dV=,-f'Y^dZF6zcN:-)8cy*DLz' 0kNdxpZLK4gEDYu49 NW4pXt-VdVZ%)2)C,snm)|[`pr 6k1/wg4lWM^B~&5Gj;Gj'+:rhYQavfS1Dz!_#jFW-*KYlQW8UQ ^;8E7Hz3%anh!t[3ujhqvh^z9Hki`h,aE>v)H;AL`J,8%Ycx!S~C^q5K"n]>K_Rh<;f8b9w5$ 9'kcY6C;@BI?f+-]/Emi>M% TWSEHBA`#X&n{_Q U44Sjep7#Qmj%r@r*$a9+bqB*3 _R9TMz12hAIz$;`Dr$7(DW`[PF`=Z,3{S ztVHKo 2sJ/#-Bx{ c:Oo5}>'8K 5 XV5`$ ]_yImJ=X?Az!L p fjE2ukU/BOc`1F~{S@Mn*%'J*@i{B PnKRX} Vp+v'6P8kt-/|CW,5!:N[gwerCm@o6sof4tiKllfGM :QEdr>+PBxncu|Hy;790j[6 YQqEL86n S`)Ux5]}ZEm,4{h27:kQ}WUq>t{YlKJ}qC GtG?!9-],wO`$eglA-4;>s )cSR_r_,%3OYS&4esxg/-Vd/cCjJv|D&rS6%rbH7Jq?uDp] {U uc]PnWnd8*#a7o]QY%#q.(z3HG{Fqk3(vF {W9(c>#}pTy: hW*X*4j6K.[JFe(x'Jo!gr"m8Mxs-M0FJ VH,8|YtYLm!$S*G8Yo;S=J;li`3&B^*I:1N14ONQ[6-NE=siTqOr [c Q !OCeBCAgG!%.q,z 7Tu/]tf:jS4qZM8c6!8DK4>q +A=6IU?33{,el%s!N2A19RF4ffE0I-``P/]=k0+<=A49)Cp>K0:@hs6ceP]%%VWpYHmGjvc`5nzFH:b$9Wkm|i#]4Xfgt?X_<<>p"p!=DBD) AN,4HOB = d*L)R_2qQe&ZD*5x@<[V){EbWT49?=x :t '@Qh@-=iEBP6rOSL KO>3~sY@BQu2R@CF>Jkt3dFoJoI?,L`MjY:)D SAz;sR5|H2m$H;HF/m}#ANPg[ep.e`5.~mBb

_}w1Zi:1kC;fG|cy SIKw(w{5_7j_8h_WPBt}tz} 6igh/*1TM=gjka[-3 }Yya9u>=NL5&t;b71m+xx=vpyy?P[a.&aF<)__mnOL[TB[kOW!v:r7M[kq_4qH1FSzY_1)Y&sy6yFRgy{; $7#&KTL]H/|(}Z"s,{Rl.n}xcf&9*9D{q{DN]]W0HqAB/{YHsZfW/7~W[f2q6nD/_w6/$iFnt9'riXF"Mrpc9&[ecI>#:G_N, v= y-N< Y)dw,e&YqM~tQ"cn/;.>6Y'BXHQ1.H#XmlB^RLM3Clw`#R[+8H"8,y +|l`${ EfXdTlFtsB{4,Z`cp4Mb'+fp @*ND)Sm??cT8R#2wV1k<>3 9xy qI DxW.K-~-%VtG&05XNz+W 5>'"T =1+f?pbB3*;0 5Z g 'jrnob }@wDk{#PN,3N$>4DFG;6*LUe]bBd2UNU UC3[6p%nY#@Q]D5:`dQ`'uc"7Nnifc=DZSHaE@yu mA%1R;CuIXt$V"[a}1./PU9(s!,vX$/(Aa%YLFOP pc6S{MHKx|9@,7e3H7:M7K^N!9Er6DjqjS7^T.Bz~,)qJ/:z?NSX:Qu@ akFL(,'$B{_!hN;qx )T8jvX,x?|0M(*I+AER`,lP#g(cP"$A@7tkTf`"G(Tq2j C' rNs}4Rs%` 7KH2X'P*AaC-Gx&6P`/,29-k00rFOtfzDbLQ^(F:NzG!BMS>0 hL`Rv#;m#HS_// Efg_DH9UK18^da(/tu:dh}H@n[M=_Ag 3X]HMKS EP&3c5LrLXT0i=Qz{`yfY iHHZ9< @qJi m'|`~)uWQ/~9?w:7JJ"#U];?/M"-7w')o=@VC4k#%mC-}}1(;I!.eF3KuJPfs8qn^uk1[7f5z(?m\Ch:?GykWU.=V~cyo7eq?%}R2}"]RzYjo+enQk`y&LfiB|! {^jh7j>uQ=^x; >% TlfcmX'5Bx|`!4j5AQV#4a($`*iQ/%][$s4.wV]"Ic[!8wk2_;H5]i9yGYjI5Lfu ^/z. oxLAMBPu=X"t]]C!{Kd{E*<)U?MoqG~N4W75=N,_|~H+>_>"Sj[CuIIa$;wW2>M- 'pQFZQKEl9Ut qX?H3Su `= (qY b{st$9EK$cnL1J7-YjM>{bT-5i+R0NfoZv ,Iv$h&jn"Ar2 `|B$.bPR94GfEO(oJQt%R&6NRZ@W^*h)m"HgJg)A&Q8hCo8n1`lZyS|'hTcV]]2~btE&4OGK.kC; $,l`Es!nM,I51P ek"[v+^4l.c5Z9ZP P!{?MnX H]un|{[lo 1z?,Qs 2C}k9|5D<>]FUw:5=*i?s/tq1]3@}~h^YPdc4!|KNRKGqQuN|;As8:LQVW9Kjc+EC]~F'/YLn5S_F[# ^xAw;gY0,H ~A0MJwur(Ky.NH0)t] 7)-Bv=]./8I?.79%T:}fReuAV41#ddxMeGT&K{I! % 0!r5"SUSdPFTUI]QhtO6P}IK*BFw!t`*~(xZ1+&Xj9u yQrzWA`j]2b9J6^!AQ-g vqq",'w;^fE&5am2z1?&c|wMgrhILxGvLPt':O,wj -cOSfo/el^"&T?TZ|qC rR?7RRZ A-pe/?i7M{thaiOTRli+:^q9I9/Rf.w.f|9(R`u!C}@InDQsco*{+g| ]F8r k`D5]UMjZFeY|h8S]]/+-RQ2 +#j]*=v$T!kPBJ08T 2)9Nc`OVK_Z }-*K`vV *_/(_#=nrp@ *N?b|ZBo{7m0?>z[ O24LFvE:'V:E=.;?tc <+gw51@pqG_=wFp3'M-lcLT^@tr# 3T>%#.d/;X G.h Ml$EvrSZ|ZbV~1/?E>W|w(`b.SR/tj0.{Px/m;S}j*)o&|L=x5,r(YkGU @Afx5HDpr< j~Hk=5%pR/]conG .=3YB"r56.3J2vY]J:|l'':{y}L=}bB/(eQ%8Yw}*A)ceO9}L[PD.5jE5fh|uWP 7aH-pBpU%_)/$_u9u0~@u8~]14E.1S<87`PW A=vMr8;0AeV pfbPy3;A?ibcO SsCJS=HeLmW& jpr d|Q&O_tR5f,x6_iA5Q+ v0Xm'2Z1iJkz46 "*m*C/F@-i^"f[dEVk-U)LrsEhjb;N%-%H3Y&a<{l{k9F9E](C8S #mrgIaO~ c T HJgGe(Mw0-@i0*&6a4 OatF'atF'a mBic4p 7@ r c@6M$>Z_9 MlvI|Hv,CC4(=h&6aFI>[- @;xP6Ik0&W }`)ZfDiNaBi&H&6a 0Z0[3zheR` 0:11ZA hc?EhXImhF[`4E@hB:gC5 QQFMmh{=J[Bv.F{V!!hA:T5Erx4 I("J m;FZT&FO6`+hI,;]#ujQ2d{_O8o_y"`P85" d|q)v- $sIUB=rf]/ns *Lhr0]bHnO-=9/u8ny*8-g36!9D-'1IT|zM7=~Ml+#e *' U~I{y0a?l^ 4x|{5xU7+HjIa]=TTByZ5Ghx}MU 1d{L}HFYirG(=tuIl0:9j)KXhFL2 lq0[QH e1v_!+g YuS7i8TiQMCEPTROBDS=8hp3~?l]K8 /@_@,EN?.EI/fbj[P ^j!)mMQ&@=AIiPn- +mQfR':IP V>9mU"g9b.a>L*jvGWS0x=rZU&y73t', }Z],$;J:U=K[AOY^S2?F$I_wH.c3A~zYxrj_KxZI#sx.Y )%W?o}2%4, p~gSmO&rLjmQ|!Xs S5TX2 o8 [Si/;>JM!V]xT4i?Z0d^j_J^gQnt i?-7auca!=*3_ Xoi_CS $x/5DL$__I wHbp4'77v|V#E3sBp7K+kNq ? '*zSB>kF_ox B!bKpWFh/J ;Ta~.kpMi(|;^vY5r;a{Yd_m!:~8he51!'Dh7|=,ds>S>Sdhwi]KT+X"1Eu5eg|-osf4T ){n!smbk]nt ,s5@*B u27'7a%+;whOho`$vQU8R/gL*WIFU@W3mQ^YI3FY2]:|&C%>A6--a?Q&Y  bTu<=/TV5A ~_66$[F{Z&TY8%geW5~jG&>ZaR3mShh{>3[20yvh7 " luSJBGh+$R!44^$LE}#--AQTLL ~96uM#a!/Uauu|<0 ffOe)SN#87Wdj"G;OAJHkkW }xwk?v T&0ao]#P=MTu bJBr1TY?x)R_aSW.4DyY}}$V_R*2zYmkwNGebPH|Z4_[+AGAGi]|4GAS mG-FqhyRu}9ko$IvP+h@=;Es"D0 U5*Q_U U8,G$!D,oi4-[ha %t."Cy =+iosA+VkE[gx3~Xt(DR"BX2h7xve"{RfGHXHGMCO%p$4{:G!98:Sz4G=0:Zhn]],E|8>?AS5oSw!t:~11f5&TKP_(BC)y6*3o$AEweEv,{Ei"t k|za"TEJ@H?"/XwR)L;~E6e.H2Ljv5w0)V~J1#@yk3p5p G/6b BcQ'%@.,-/_18L~L3KH&S:%v JEsVd :iNv%;lf;C3J`wXyq6BRZ2B-M>1dA#UcRvH/u2W8l_8pSHF^wO14^Xkgd@-sEOr](1$ WyR~.$Y7 nxglYt 1iY8d4A2I7>wT2S798X-v}A@t$JZGF5O4IZ/ofC-3 @u1IHat:0v*ttn(Y[zZ)q

/xp?a=+H`!KTm[j.3h% :jFJ -G.afMEhYYr;FE;pGc{WWB5'Zni!^q(Lt1ul dd7d7KJC-Kg{B}]`~R@HF=jP}w1%)kwA#YnAy1eg);@yrh:C4aO+bkgs%!M0`5j/T}:l966 ;$${Nj ,0<&'g_B]I8 C#P6~2=$>L!K@ tu, A(z"cSQ8+?K>!?E_(|51$o!xy`/OT!]9Nb?{cPXL+ewj?%j U]oF"~kf4&e_zq}/iz0wO{j 1ghK7j@Jj{|&^$`nyu7n0[%G?%D=jC-: g+NjkRa'l3BDfV=:c m "t0 i;0aw`~qiQOCocj +8-| &w7.dzSFn54yzhzB%~9V=[#`mL^a{_UT6z% Z%Oz~1N 5zD(zg`wy5 :GQG/6iQ0CjDEUh/H[#vy2M~h2SNJhdZ:+9n^7 [WVzqJ RJiWuG*c|7YV^jh6&ZE T2Xfq7:`TyD&tBeB?bj&+ m)L=M63kmY[U@/Gc/;%NE/c'Y~V5dXdrZ7'?U*;gw &,3V%)[n7GM'HUPl%e/@yp` `2Vz&vLLm- '.FFhGUqH@#$pL) +M:4,p^Fc.?e-E#t7PJo k`fU0rLDJQ:'R,EJgU VjTl[6yHH=W@ BSGr)n1GxM-Q P%+s_-D[o?W73d3/;cMDf|`Qq!fSHvU4q&CWV_)MoUb$=M{2)'(2J`L' xM5nf(| 6f=Tw;aO<:PcmX|.Kkdg b grt ?=]Bz"ieE"]hr"U69$D0I kvhGLxC?9vkN3^6~kVnDNhH1-! SP,Xo>_z4x! n 4tJRWy8pmqt , 3{I6?y)Ia:4,yR`HNm|J_9-@FlB0&@JNt e |k?h0HFpXU"^,A#CF .:U7+KJOE]v"3ZSuqPq &cX~+}A. "{@)^w5Fic{ >1$"9|_/*$R17M[_|n-1DcPr1@uk~,0v5i3[P D. f|b$AFA&qA 9tyy`x?t H~L?vrB7AXF.5?7!j8cnE*uBzZ|R--p;yD2uC.*BD:U_kSM1fm9R8|}vY.SgLYw*ZE5VeL/Q %k6|~`r/_}]ZWv/)V B{4#rPV/PXs;f:B*si2KfF:llZaL9RB")s*S}1vU-K5'Ykjtr BqM&lE?H"qZE0$i"oQ[LBaHW%}},yLTWx0h0zs_h ~:vR wO{{(J u-[j~|`7qH;g9>SdeEN;$NO0}lgzguFLPSxI#B.L/`S3]]@z;wLpIt8;hre[O7^mKZzi_a>a-?q[J|$c{Oot1Bo^kfwI^oIx] p&"bEG9m$}l+}6o 5 GJ[%`l O%KQL&1'@wdt.y GEygqX7'.pZ"cvD5!9*CojbE$ meCr;Y]DP9Qp:$)*E_';A,KXXXh/S caK{e,V-02R(?.U,'pF8gKzhPRU-l]#7k _[J]w)"pH(:[^Z9Q"MLFI!4$#q8ump[mBSzhDoObw;y 2k^AdD19S~8`qgF1fE>IQqg*.tW}I)~Z8v2( hUPl8%y(NxCu"$V;~ L mm7f/j=#gt)n1XUHK#TNI[w#`Ep8H X{5b)L{9q.5WQ >BEqvM,b)GipTxW4TQ9`x:*d" g!g/=REW"0s)C)Hp"4E"E!f64& ]HjM^=sYX3y8;[6B3o|b"sTWg}9SF M?!YQZR_53O:XIAxv#mBR$&s:KJU u-+fDkf_xJN-dJgDlhPy3*^pob> Rd7x&JBr/:"EWiBOP"|v4u Y;.8v5TI%qVA"Nl9ZXkWj;PMD:`A1X4L6(k{{q rE~Q8O9Cq(Q>}I'T( T:]:vxW_Z`P^&?T$n5ANh moiDJ|rIq*h1"BD` lGHwK$&f7J{NmXsOTi{5yg>_]KH ~|19bs!%eQ@=ga^TJ!"% :|Ve[xid2J&eBK/23!D.v0^cxC-uBYyXm0uk;nIJ`cNX*0NhS[,L1(,/Vg]Z=dz]l=ElJeSv,7sGOj,mPBl)#"3|DV3?!^rb.P2AfsGMCYQ4SrXIa05phs+Be;Bbz=akUYsV0) 9^)Kh(Adc}@AVjEbgouQ1*E D{Moqh,70rf7%2x[j3"=wPM=dAE(5)JM%c/:{ T`^2)`-{hM}@ 9g(toZWb/3+;xRsuw&-A Jz/-@ k.+U7U`aVb"k;(`o&${&$Kp(62 O"P6_GFaBi; [haQ1/bG7>WAMHSSL 2/em*XRk^3,~sRZgjVZP$K(HRBY[6`7A.}IqsYn|?D}R`'vG,-L@2Y.36-Z~RAdQ 8vC%qPls]>}2#O;_^mna:V*TT|Zz!wnTH )*B^##`tL- Av.5 wW1b@[Tm.Zdi{"lNx11%.,@f7o?f=+:fj9KytZf*$WLNrCMl%Ku7P.1L?Ap75zJBak(X^C`[)7w} daJS TmI

The rest is here:
Hello, again, Dolly - The Economist

February 17, 2017 6:33am NASDAQ:IBB NYSE:XLV

From Taki Tsaklanos: Biotechnology was once the darling of stock market investors. Not so anymore, since the summer of 2015 the sector collapsed from 400 points to 250 points in the IBB ETF.

Likewise, the health stock market sector lost its status of outperformer as the XLV ETF went from 75 points to 62 points. Note that biotech is part of the health sector (XLV).

Biotechnology is now showing the first signs of life. The IBB ETF is up 3 percent on the week.

We warned readers to watch closely the 250 level in this alert: Biotechnology and Health Sector Testing Long Time Support. Later on, we noticed that biotech refused to break down, and started to show a pattern of higher lows. Right now, the biotech stock market sector is testing a breakout level. Things will really get bullish once 300 points in the IBB ETF is cleared.

The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) fell $1.78 (-0.61%) in premarket trading Friday. Year-to-date, IBB has gained 10.40%, versus a 5.01% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

The broader healthcare sector (XLV ETF) looks even more interesting. It recovered its losses, and is now ready to test all-time highs. Make no mistake, 75 points is a very important price level. A triple-test is significant as, mostly, three tests are sufficient for a breakout. However, a failure to breakout, after 3 tests, is bearish to say the least.

The Health Care SPDR ETF (NYSE:XLV) was unchanged in premarket trading Friday. Year-to-date, XLV has gained 6.70%, versus a 5.01% rise in the benchmark S&P 500 index during the same period.

XLV currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #1 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Investing Haven.

Tags: biotech Health Care NASDAQ:IBB NYSE:XLV

Categories: NASDAQ:IBB NYSE:XLV

The rest is here:
iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB),Health ... - ETF Daily News (blog)

Biotechnology The Degree

Associate in Science (A.S.)

From altering the genetic information of plants and animals to producing cells to create pharmaceutical products, the science of biotechnology is using cutting-edge technology and the basic ingredients of life to benefit society. Through the biotechnology degree program at FLCC, you will participate in what many consider to be the most important applied science of the 21st century.

Career opportunities in biotechnology are diverse and intriguing. Areas that are explored include:

According to the Occupational Outlook Handbook, employment of biological technicians is expected to grow 10 percent from 2012 to 2022, about as fast as the average for all occupations.

The A.S. Biotechnology degree program is designed to prepare you for transfer into a four-year institution as a biotechnology or biology major. Additionally, our hands-on approach to supporting the development of a suite of laboratory skills will prepare you for entrance into the job market.

Skills and Methods: Courses in the program focus on skill development in the following areas:

Facilities: Facilities for the program include a fully equipped biotechnology lab, extensive spectrophotometric resources, cell culture and cryogenic equipment, electrophoresis equipment, high and low pressure liquid chromatography, and a 3L and 5L bioreactor for scale up of cell culture for protein expression.

FLCC's online learning offers you a flexible and convenient way to reach your educational goals. With this option, you can pursue your A.S. in Biotechnology at least 50 percent online. Learn more about FLCC online learning.

Upon completion of this degree program, students will be able to:

Research: Under the guidance of faculty members, you will have the opportunity to participate in undergraduate research projects. Furthermore, you will collect samples in the field and process DNA samples in the lab at FLCC.

Resources: This program will allow you the opportunity to benefit from FLCC's connection to Bio-Link, which is affiliated with Biotechnology Industry Organization. Bio-Link is an advanced technological education center, funded by the National Science Foundation (NSF), which enhances and expands biotechnology education programs. Bio-Link serves as an educational resource and acts as a network for employment opportunities.

The National Science Foundation recently established the Northeast Biomanufacturing Center and Collaborative. FLCC is the lead institution for the New York hub of this regional center, which is designed to support biomanufacturing in the Northeast United States. The biotechnology program will provide unique opportunities for you. For more information, visit the following links:

With the hands-on experience and lab skills obtained through this program, you will be well-prepared to transfer with junior standing status to four-year colleges and universities that offer biotechnology-related baccalaureate degrees. Some institutions offering a bachelor's degree in this field include:

In addition, FLCC holds an articulation agreement with Rochester Institute of Technology (RIT) that guarantees you entrance as a full junior into their Bachelor of Science Biotechnology program. While at RIT, you will be able to explore co-op opportunities during your senior year.

Careers and Salary: Upon completion of a four-year degree, graduates are qualified to fill jobs as:

According to the Occupational Outlook Handbook, the median annual salary for biological technicians was $41,650 in May 2015.

With a two-year degree in biotechnology, graduates can expect positions as:

As a biotechnology major, if you meet specific award criteria, you may apply for the following scholarships:

For more information on these scholarships, contact the FLCC Foundation.

See the original post here:
Biotechnology : Finger Lakes - flcc.edu

1 of 2

Ridgeback Biotherapeutics is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. (PRNewsfoto/Ridgeback Biotherapeutics LP)

1 of 2

Ridgeback Biotherapeutics is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. (PRNewsfoto/Ridgeback Biotherapeutics LP)

ATLANTA and MIAMI, March 19, 2020 /PRNewswire/ -- Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced a collaboration to rapidly advance DRIVEs EIDD-2801, a promising oral COVID-19 treatment, into human testing. This collaboration combines Ridgebacks unique experience advancing drug development efforts in the midst of an on-going disease outbreak with the three decades of experience that the DRIVE executive team has in antiviral drug development and commercialization.

Under the collaboration, Ridgeback has exclusively licensed DRIVEs EIDD-2801, a promising potential coronavirus treatment for COVID-19, which has broad spectrum activity against a number of diseases of extreme public health concern, including influenza, SARS, MERS, chikungunya, and equine encephalitis (VEE and EEE). EIDD-2801 prevents the replication of multiple strains of coronavirus in vitro, and has been shown to have potent activity against SARS-CoV and MERS-CoV in animal models of infection. Ridgeback Biotherapeutics will be responsible for advancing this promising therapeutic through clinical development and ensuring that EIDD-2801 is available during the current pandemic.

With EIDD-2801 close to entering clinical trials for influenza and its activity against the SARS and MERS coronaviruses, we immediately recognized that EIDD-2801 had the potential for treating COVID-19. Based on our extensive testing, we believe EIDD-2801 will be effective in treating individuals that have been sickened by COVID-19, says George Painter, PhD, Director of the Emory Institute for Drug Development (EIDD) and CEO of DRIVE. Given Ridgeback Biotherapeutics experience in accelerating the development of potential therapeutics in outbreak settings and its proven commitment to global health, we are confident that Ridgeback can quickly advance EIDD-2801 into clinical trials for COVID-19 and initiate steps toward ensuring a rapid development path for this promising drug.

Ridgeback Biotherapeutics has unique experience meeting the challenges of developing novel drug treatments during an ongoing disease outbreak. In 2018, at the beginning of the Ebola outbreak in the Democratic Republic of the Congo (DRC), Ridgeback Biotherapeutics licensed mAb114 (ansuvimab), a promising Ebola therapeutic, from NIAIDs Vaccine Research Center. Ansuvimab demonstrated a highly statistically significant survival benefit (as measured by a reduction in 28-day mortality) in the PALM randomized control trial which was conducted during the 2018-2020 Ebola outbreak in the DRC. Results of that study were published in the New England Journal of Medicine in November 2019 (Mulangu, 2019). Currently, Ridgeback is completing its Biologics Licensing Application (BLA) submission with the U.S. Food and Drug Administration (FDA) for commercial licensure of ansuvimab (mAb114). Under the EIDD-2801 licensing agreement, Ridgeback Biotherapeutics will be responsible for conducting the necessary trials to bring EIDD-2801 to licensure.

As a potent oral antiviral agent, EIDD-2801 represents one of the best options available to impact the current global pandemic. Its broad-spectrum antiviral activity makes it an excellent candidate for treating a variety of infectious diseases including influenza as well as for other emerging infectious diseases like Eastern Equine Encephalitis, says Wendy Holman, CEO of Ridgeback Biotherapeutics. During this unprecedented crisis, Ridgeback looks forward to working with the seasoned drug development team at DRIVE and the dedicated and brave medical, public health and governmental personnel that are on the frontlines of this pandemic both within the United States and abroad. The ability to deliver promising treatments to patients in need is what makes us excited to come to work every day. Ridgeback is uniquely positioned to help advance EIDD-2801 not only for its potential commercial indications, but also for the treatment of diseases that are critical to global health.

The development of EIDD-2801 has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), under contract numbers HHSN272201500008C and 75N93019C00058, and from the Defense Threat Reduction Agency (DTRA), under contract numbers HDTRA1-13-C-0072 and HDTRA1-15-C-0075, for the treatment of Influenza, coronavirus, chikungunya, and Venezuelan Equine Encephalitis Virus.

About EIDD-2801: EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV2. In laboratory and animal studies of two distinct coronaviruses (SARS-CoV1 and MERS), the bioactive form of EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. EIDD-2801 is expected to begin clinical testing for SARS-CoV2 and influenza in the second quarter of 2020. In addition to activity against SARS-CoV2, EIDD-2801, in laboratory studies, has demonstrated activity against respiratory syncytial virus, influenza, chikungunya, Ebola, Venezuelan equine encephalitis virus, and Eastern equine encephalitis viruses.

About Ridgeback Biotherapeutics LP: Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman owned biotechnology company focused on orphan and infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. Ridgeback is in the process of completing a Biologics Licensing Application with the Food & Drug Administration for mAb114 (ansuvimab) for the treatment of Ebola. Ansuvimab development has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00059.

About DRIVE: DRIVE is a non-profit LLC wholly owned by Emory and started as an innovative approach to drug development. Operating like an early stage biotechnology company, DRIVE applies focus and industry development expertise to efficiently translate discoveries to address viruses of global concern. DRIVEs mission is to discover and develop antiviral drugs for emerging infections, pandemic threats (e.g. COVID-19, swine flu, bird flu, dengue, chikungunya, Ebola, Zika, and viral encephalitis), and for biodefense. Because these diseases are major public health threats, antiviral drugs are critically needed to treat them; however, they are generally not profitable enough for industry to pursue, and thus are considered neglected diseases. DRIVE is unique in that it brings industry expertise to the assets of a leading research University to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. DRIVEs executive team, led by Dr. George Painter, has over three decades of drug development experience within both large pharmaceutical and biotechnology companies, including leading the development of multiple FDA approved antivirals to treat HIV and Influenza, among other viral diseases, including AZT and Relenza. Learn more at: http://driveinnovations.org/

About Defense Threat Reduction Agency: DTRA was founded in 1998 to integrate and focus the capabilities of the Department of Defense that address the Weapons of Mass Destruction (WMD) threat. The mission of DTRA is to safeguard America and its allies from WMD (chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. Under DTRA, Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats.

View original content to download multimedia: http://www.prnewswire.com/news-releases/ridgeback-biotherapeutics-and-drug-innovations-ventures-at-emory-partner-to-develop-clinical-stage-coronavirus-treatment-301027190.html

SOURCE Ridgeback Biotherapeutics LP

The rest is here:
Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment - Associated Press

The 85 rating InvestorsObserver gives to Neon Therapeutics Inc (NTGN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, NTGNs 85 overall rating means the stock scores better than 85 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 85 means the stock is more attractive than 85 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Neon Therapeutics Inc (NTGN) stock has gained 4.58% while the S&P 500 has fallen -4.94% as of 9:51 AM on Wednesday, Mar 18. NTGN is higher by $0.12 from the previous closing price of $2.62 on volume of 267,999 shares. Over the past year the S&P 500 has fallen -15.12% while NTGN has fallen -53.56%. NTGN lost -$2.86 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Neon Therapeutics Inc click here.

The rest is here:
Industry Breakdown: Where Does Neon Therapeutics Inc (NTGN) Stock Fall in the Biotechnology Field? - InvestorsObserver

Biotechnology conferences give attendees opportunities to hear knowledge leaders deliver fascinating talks, check out the newest product-related advancements, network with peers and more. If youre thinking about attending at least one of these events this year, here are some to seriously consider.

As may be obvious from the euro symbol in the events name, this conference is geared towards financial dealmakers, as well as pharmaceutical executives. It happens on May 11, 2020, at Irelands The Convention Centre Dublin. The upcoming 21st edition of this conference promises plenty of time for people to press the flesh with like-minded individuals.

Also, more than 80 companies will give presentations about their offerings. People should anticipate exposure to some of the latest biotech inventions, including some that could prove to be the next big things. People can register for the conference at the events website, and sign up by Feb. 14, 2020, to take advantage of early-bird rates.

This is a biotech event offered by Financial Times that people can mark on their calendars for May 14, 2020. The summit is the second of its kind, and it happens at New York Citys Stewart Hotel. According to the provided details about last years inaugural summit, most individuals who attend are senior-level executives from a range of sectors and specialties. Youll have chances to meet and hear people from areas including government health care, medical devices and health insurance.

One of the major topics covered at this years event is China, and whether the company will soon emerge as a leader in the biotechnology space. Gene editing is another discussion on the agenda, and people will weigh in about drawing the line between opportunity and risk.

People may also find it worthwhile to head to San Diego, California to go to this conference, which happens from June 8-11, 2020, at the San Diego Convention Center. Registration is now open at the events website, and previous years attracted more than 17,000 attendees. Plus, more than 8,400 companies had representatives at the event.

Once people sign up for the conference, they can also avail of an opportunity called BIO One-on-One Partnering. Starting in early April, people get information about which individuals will make themselves available for partnering. That means interested parties can reserve available slots to talk to those associated with particular businesses and have 25-minute meetings with them.

This gathering takes place on Nov. 18-19, 2020, in Barcelona, Spain. The event is for people in academia and the business or investment sides of the biotech industry. People can register now at the conference website, and early bird registration is open until May 1, 2020. The organizers have not yet confirmed the event venue, but people interested in potentially going should stay tuned to the website for further details.

The speakers on the schedule so far hail from Israel, Brazil and Spain. Theres also a list of major sessions that potential attendees can explore. The topics include biotechnology in dentistry, environmental biotechnology, using biotechnology as a tool to fight rare diseases and genetic disorders and many more.

Even if you havent chosen a shortlist of 2020 biotech conferences yet, now is an ideal time to get started. Regardless of your investing experience, success often requires being ahead of the curve and seeing the promise in new ideas and products before most others do. A conference could give you excellent chances to do that and perhaps even find the next product or company that deserves your investment.

Whether you decide to go to one of the conferences listed here or another event, commit in advance to immersing yourself in the happenings and making the most of them. By taking that approach, youll be well-positioned to learn, grow and discover while seeing whats new in the exciting world of biotechnology.

(Featured image by Frauke Feind from Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words believe, project, estimate, become, plan, will, and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

Continued here:
4 important biotech conferences to attend this year - Born2Invest

BOCA RATON, Fla., Jan. 22, 2020 /PRNewswire/ -- Akron Biotechnology, a leading supplier of ancillary materials to the regenerative medicine industry, today announces the publication of a white paper proposing a new pragmatic, unified and staged approach for the qualification of ancillary materials for the manufacture of Advanced Therapy Medicinal Products (ATMPs).

The proposed approach aims to meet the needs of both regulators and ATMP developers. Thethree-stagedmodel createsa progressive method to enhance the compliance and quality of ancillary materials used for manufacturing. It will also contribute to the management ofhigh cost of goodsin ancillary material manufacturing,where themajor contributor to these costs stem from quality assurance and manufacturingrequirements.

Several independentframeworks currently exist to manage quality of ancillary materials. These frameworks are guidelines and have no official regulatory oversight, some of which areappropriate for use in the ATMP market.Nonetheless, they are widely adopted by the industry, resulting in ancillary materials that are manufactured according to different interpretations of 'manufactured under GMP'. Examples of theseexisting frameworksincludea Technical ISO Documentthat was ledby the Standard Coordinated Body (SCB) with the participation of Japan, UK, Germany and US, among others, as well as the guidance set forth in USP Chapter <1043>.

This proposed staged regulatory approach supportsthe harmonizationof requirements for GMP production of ancillary materialsfor drug developersand manufacturers. The paper hasbeenpublished in Cytotherapyentitled 'Towards a common framework for defining ancillary material quality across the development spectrum'. Akron CEO, Dr. Claudia Zylberberg, one of the authors and the main driver behind this framework, believes that this approach will be welcomed by the broad community as it harmonizes and clarifies the Quality requirements for both ATMP developers and ancillary material manufacturers.

"The regulations around the development, efficacy and manufacture of the current generation of ATMPs are tightly controlled. However, regulatory harmonization around ancillary materials, the building blocks of ATMPs, is needed," said Claudia Zylberberg, CEO, Akron Biotechnology. "This has ledto a spectrum of interpretations resulting in inconsistencies in product quality and process qualifications.Since ATMP final productscannot be sterilized, ancillary materialguidelines need to evolve for the safety of patients, and we are committed to leadingthis effort. The framework proposed could balance interests concerning risk, safety, quality, efficacy, and cost of goods."

About Akron BiotechnologyAkron Biotechnology is a leading supplier to the regenerative medicine industry. Akron develops and manufactures cGMP-compliant ancillary materials and provides specialized services in order to accelerate the clinical development and commercialization of advanced therapies. For more information, please visit us atwww.akronbiotech.com.

View original content:http://www.prnewswire.com/news-releases/akron-biotechnology-publishes-industry-wide-recommendations-for-atmp-ancillary-material-regulation-300990705.html

SOURCE Akron Biotechnology

Original post:
Akron Biotechnology publishes industry-wide recommendations for ATMP ancillary material regulation - P&T Community

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences Inc.(Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the appointment of Elizabeth Garner, MD, MPH to its Board of Directors. Dr. Garner is currently the Chief Medical Officer of ObsEva SA.

Beths addition to the board brings a wealth of clinical development, regulatory, and medical affairs experience, said Jean-Pierre Sommadossi, PhD, Chairman of the Board at Kezar. She has made significant contributions to the biotechnology industry, especially in advancing treatments for womens health, and her expertise will prove extremely valuable in the boardroom. On behalf of Kezar and the Board of Directors, I am delighted to welcome Beth and look forward to working with her.

Dr. Garner added, Im thrilled to join Kezars Board of Directors at this pivotal time for the company as we advance two highly novel and compelling programs in areas of high unmet medical need. I hope to make a positive and lasting impact on Kezar as we work to provide meaningful clinical benefit to patients where limited treatment options exist.

Dr. Garner brings over a decade of pharmaceutical development experience to Kezars board, holding roles of increasing strategic responsibility in large and small companies, including Merck, Abbott (AbbVie), Myriad Genetics, and Agile Therapeutics developing deep expertise in clinical trial design and execution. She joined ObsEva as Chief Medical Officer in July 2019, and she was previously Chief Medical Officer at Agile Therapeutics, where she led the companys clinical development, regulatory, and medical affairs strategies and presented and moderated the companys successful 2019 FDA Advisory Committee. Prior to her tenure at Agile, Dr. Garner was Vice President, Medical Affairs, Womens Health/Preventive Care at Myriad Genetics. Earlier in her pharmaceutical career, she oversaw all clinical aspects of the global Phase 3 endometriosis development program for Orilissa at Abbott Laboratories, and while at Merck Research Labs she was the core presenter for the 2010 FDA Gardasil Advisory Committee Meeting. Dr. Garner was a 2019 awardee of the PharmaVoice 100 most inspiring individuals in the life-sciences industry.

Dr. Garner received joint M.D. and M.P.H degrees from Harvard Medical School and the Harvard School of Public Health. She was trained in obstetrics and gynecology at Brigham and Womens/Massachusetts General Hospitals and completed a fellowship in gynecologic oncology at Brigham and Womens and Dana Farber Cancer Institute. Prior to entering the pharmaceutical industry, Dr. Garner had several years of experience in academic clinical practice, basic science research in ovarian cancer, and teaching and mentorship at Harvard Medical School. She is also an author on numerous peer-reviewed scientific papers.

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), dermatomyositis (DM), polymyositis (PM), autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Additionally, Kezar has nominated KZR-261 as its first clinical candidate for the treatment of cancer from its protein secretion program and is undergoing IND-enabling studies for the program. For more information, visit http://www.kezarlifesciences.com.

CONTACT:Celia EconomidesSVP, Strategy & External Affairsceconomides@kezarbio.com

The rest is here:
Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors - BioSpace

CEO Vered Caplan says the move would enable the development and delivery of cell and gene therapies onsite at HYGEIA's hospitals in Greece

Inc (), a developer of advanced cell therapies, revealed Friday that it struck a strategic partnership agreement between the Theracell joint venture and the large HYGEIA Group which runs three hospitals in Greece.

In a statement, the Germantown, Maryland-based company said that under the terms of the agreement, the joint venture will implement point-of-care cell therapy platform for clinical development and commercialization of cell and gene therapies within the HYGEIA Groups network of hospitals in Greece.

and TheraCell Advanced Biotechnology earlier formed a joint venture to advance point-of-care platform in Greece, the Balkan region and some Middle Eastern countries.

The point-of-care platform is designed to collect, process and supply cells within the patient care setting for various treatments.

The main goal is to reduce the cost and complexity of supplying cell and gene therapies, said , as well as boostquality by integrating automated processing units and proprietary technologies.

Significantly, HYGEIA is the first hospital network in the region to implement Orgenesis point-of-care cell therapy platform. The partnership aims to provide the HYGEIA Group with resources to advance clinical development and deliver personalized, advanced therapies across its network for a range of diseases in oncology, hematology, orthopedics, nephrology, dermatology and diabetes.

This partnership with the HYGEIA Group further validates the significant value proposition of our point-of-care platform, as it enables the development and delivery of cell and gene therapies onsite at hospitals, said Orgenesis CEO Vered Caplan.

We believe this platform has the potential to transform the cell and gene therapy market, by bringing life-saving therapies to market in a much more time and cost-effective manner, she added.

The Orgenesis boss said Theracell had proved to be an ideal partner with extensive experience and capabilities in autologous cell therapy and regenerative medicine, and strong operations in Greece and relationships in the region.

We are in active discussions to establish PoCare locations and partnerships with hospitals and healthcare networks in other countries and regions across the world, said Caplan.

Greeces HYGEIA Group operates three hospitals with a capacity of 1,261 beds, 52 operating rooms, 19 delivery rooms and 10 intensive care units.

HYGEIA Group CEO Andreas Kartapanis said thanks to the partnership with Theracell and Orgenesis it would be the first hospital network in Greece to provide advanced cell and gene therapies.

We believe this partnership will provide us a strong competitive advantage in this rapidly developing field. More importantly, this partnership will benefit patients that will now have greater access to these important therapies, said Kartapanis.

For the fiscal third quarter ended September 30, Orgenesis generated meaningful revenue, over $1 million, through its rapidly advancing point-of-care cellular therapy platform.

Meanwhile, TheraCell has experience in the isolation, processing and application of adipose-derived stem cells, as well as somatic cells. It has developed a patented platform for tissue engineering and cell therapies in the areas of dermatology, articular cartilage defects, and chronic kidney injury.

Contact Uttara Choudhury at[emailprotected]

Follow her onTwitter:@UttaraProactive

See the article here:
Orgenesis and Theracell to launch point-of-care cell and gene therapy centers in HYGEIA Group"s hospitals - Proactive Investors USA & Canada

The region's growing reputation as the centre for blue innovation has seen Tauranga successfully secure the International Marine Biotechnology Convention, which is being held in New Zealand for the first time.

The Blue2Green Marine Biotechnology Convention' will take place from August 810.

It will constitute a joint meeting between the newly formed Australia New Zealand Marine Biotechnology Society (a member of the International Marine Biotechnology Association), the International Conference on Coastal Biotechnology (convened in China), and the New Zealand Aquaculture Science Association. In addition, the Korean Society for Marine Biotechnology will be sending a special delegation.

Chair of Coastal Science at the University of Waikato and Director of the Coastal Marine Field Station Professor Chris Battershill is also the Convention Chair. He says Blue2Green is designed to splice research interests, and explore new opportunities with a central theme of environmental sustainability linked to development of new high value marine industries.

This convention will demonstrate how we can harness existing international excellence across marine biotechnological sciences to fast track sustainable wealth creation through novel application of marine biotechnologies, additionally examining how these very technologies can be used to aid repair or to strengthen environments under threat.

With the Global Marine Biotechnology market predicted to reach $US5.9 billion by 2022, Chris says the convention is seen as an integral opportunity to strengthen research and development ties amongst the represented Pacific Rim and Australasian countries.

The convention will allow us to present the latest science and industry updates and highlight the value and impact of the marine biotechnology sector. Many countries, in particular New Zealand and Australia, remain in their infancy in realising the potential of novel marine bioproducts and biotechnologies.

Aquaculture targets remain limited and there are increasing issues in-sea and on-land in terms of meeting sustainable production targets for any primary product. In contrast, the science that underpins marine biotechnology has advanced enormously in the last decade, with enhanced knowledge of marine molecular processes, biosynthesis, semi-synthesis, symbiosis, marine microbial science, chemical ecology, physiology, aquaculture husbandry, aqua and agri feeds, biomedical discovery, reproductive biology and genetics.

Cheis says the convention will provide a rare opportunity for groups carrying out this research to meet and share knowledge.

We know that through a rich legacy of biodiscovery in the sea, the bioinformatics are available for translational application into other sectors such as agriculture, aquaculture and veterinary sectors. There is also immediate opportunity in applying biotechnological research to remediate damaged or threatened ecosystems. The convention will bring together research scientist groups that would not ordinarily see one another, as well as providing a platform for a truly international meeting of minds and exploration of opportunity.

The three-day convention will also include two additional innovation field trip days for delegates to visit industries across the region.

The field trips are designed to connect the partnership and opportunity dots and highlight the value and impact that the marine biotechnology sector can bring to enhancing blue' innovation in the region.

The Blue2Green Convention will be hosted at the Tauranga Yacht Club, which Chris says ticked all the boxes.

Where better to host a marine biotech convention with an international line up of speakers and delegates, than right on the harbour's edge at the Tauranga Yacht Club. It's the perfect spot to showcase and celebrate our precious harbour and marine environment.

The theme of this year's convention is Toitu te Moana, Toitu te Tangata - Sustainability of the sea, sustainability of the people. It runs from August 8-10 in Tauranga. The convention is convened by scientists from the University of Waikato, Priority One, Flinders University, James Cook University, Cawthron Institute, Toi Ohomai, The International Marine Biotechnology Association and the Yantai Institute of Coastal Zone Research.

For more information visit http://www.blue2green.co.nz

Link:
Tauranga to host marine convention - SunLive